Sfe Investment Counsel Crispr Therapeutics Ag Transaction History
Sfe Investment Counsel
- $434 Million
- Q1 2024
A detailed history of Sfe Investment Counsel transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Sfe Investment Counsel holds 5,643 shares of CRSP stock, worth $322,723. This represents 0.09% of its overall portfolio holdings.
Number of Shares
5,643
Previous 4,900
15.16%
Holding current value
$322,723
Previous $306,000
25.49%
% of portfolio
0.09%
Previous 0.08%
Shares
2 transactions
Others Institutions Holding CRSP
# of Institutions
543Shares Held
56.3MCall Options Held
2.91MPut Options Held
2.47M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.16MShares$467 Million3.97% of portfolio
-
Capital International Investors Los Angeles, CA7.84MShares$448 Million0.11% of portfolio
-
Nikko Asset Management Americas, Inc.3.27MShares$187 Million2.23% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.15MShares$180 Million0.13% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.7MShares$155 Million0.11% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.46B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....